This website uses cookies

We use cookies and website tracking tools to provide you with the best online experience. Learn more in our /en/privacy-notice/privacy statement.

if you accept, your choice will be valid until cancellation.

If you disallow cookies, functionality of our website might be limited.


Department of Neurology & Interdisciplinary Neuro-Oncology

Selected Publications

Research group Prof. Dr. Dr. Ghazaleh Tababatabai


Behling F, Fodi C, Gepfner-Tuma I, Kaltenbach K, Renovanz M, Paulsen F, Skardelly M, Honegger J, Tatagiba M, International Consortium on M, Schittenhelm J, Tabatabai G (2021) H3K27me3 loss indicates an increased risk of recurrence in the Tubingen meningioma cohort. NeuroOncol 23:1273-81

Przystal JM, Becker H, Canjuga D, Tsiami F, Anderle N, Keller AL, Pohl A, Ries CH, Schmittnaegel M, Korinetska N, Koch M, Schittenhelm J, Tatagiba M, Schmees C, Beck SC, Tabatabai G (2021) Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma. Cancers (Basel) 13:2400

Rajaraman S, Canjuga D, Ghosh M, Codrea MC, Sieger R, Wedekink F, Tatagiba M, Koch M, Lauer UM, Nahnsen S, Rammensee HG, Muhlebach MD, Stevanovic S, Tabatabai G (2019) Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma. Mol Ther Oncolytics 12:147-61

Walter B, Canjuga D, Yüz SG, Ghosh M, Bozko P, Przystal JM, Govindarajan P, Anderle N, Keller A-L, Tatagiba M, Schenke-Layland K, Rammensee H-G, Stevanovic S, Malek NP, Schmees C, Tabatabai G (2021) Argyrin F Treatment-Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental Glioma. Advanced Therapeutics 4:2100078

Wick A, Bahr O, Schuler M, Rohrberg K, Chawla SP, Janku F, Schiff D, Heinemann V, Narita Y, Lenz HJ, Ikeda M, Ando Y, Wick W, Steinbach JP, Burger MC, Wenger K, Lassen U, Sankhala KK, Roggia C, Genvresse I, Munhoz C, Rentzsch C, Reschke S, Langer S, Wagner M, Kaulfuss S, Cai C, Lagkadinou E, Jeffers M, Pena C, Tabatabai G (2021) Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. Clin Cancer Res 27:2723-33


Research Group Dr. Daniel Merk


Merk DJ, Zhou P, Cohen SM, Pazyra-Murphy MF, Hwang GH, Rehm KJ, Alfaro J, Reid CM, Zhao X, Park E, Xu PX, Chan JA, Eck MJ, Nazemi KJ, Harwell CC, Segal RA (2020) The Eya1 Phosphatase Mediates Shh-Driven Symmetric Cell Division of Cerebellar Granule Cell Precursors. Developmental Neuroscience 42:170-86

Pak E, MacKenzie EL, Zhao X, Pazyra-Murphy MF, Park PMC, Wu L, Shaw DL, Addleson EC, Cayer SS, Lopez BG, Agar NYR, Rubin LL, Qi J, Merk DJ, Segal RA (2019) A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma. Neuro-Oncology 21:1150-63

Merk DJ, Ohli J, Merk ND, Thatikonda V, Morrissy S, Schoof M, Schmid SN, Harrison L, Filser S, Ahlfeld J, Erkek S, Raithatha K, Andreska T, Weisshaar M, Launspach M, Neumann JE, Shakarami M, Plenker D, Marra MA, Li Y, Mungall AJ, Moore RA, Ma Y, Jones SJM, Lutz B, Ertl-Wagner B, Rossi A, Wagener R, Siebert R, Jung A, Eberhart CG, Lach B, Sendtner M, Pfister SM, Taylor MD, Chavez L, Kool M, Schuller U (2018) Opposing Effects of CREBBP Mutations Govern the Phenotype of Rubinstein-Taybi Syndrome and Adult SHH Medulloblastoma. Developmental Cell 44:709-24 e6

Grammel D, Warmuth-Metz M, von Bueren AO, Kool M, Pietsch T, Kretzschmar HA, Rowitch DH, Rutkowski S, Pfister SM, Schuller U (2012) Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem. Acta Neuropathologica 123:601-14


Research Group PD Dr. Mirjam Renovanz


Voss H, Scholz-Kreisel P, Richter C, Ringel F, Singer S, Renovanz M (2021) Development of screening questions for doctor-patient consultation assessing the quality of life and psychosocial burden of glioma patients: an explorative study. Qual Life Res 30:1513-22

Goebel S, Knuth C, Damm M, Linden D, Coburger J, Ringel F, Tabatabai G, Mehdorn M, Renovanz M (2020) Towards the targeted assessment of relevant problems: Optimization of the distress Thermometer for adult neuro-oncological patients. Psychooncology 29:2057-66

Renovanz M, Hippler M, Voss M, Wehinger J, Kessler AF, Gempt J, Nadji-Ohl M, Weiss Lucas C, Rapp M, Misch M, Coburger J, Mehlitz M, Meixensberger J, Keric N, Tabatabai G, Blettner M, Schranz M, Singer S (2020) Glioma patients in outpatient care-optimization of psychosocial care in neuro-oncological patients (GLIOPT): Protocol for a cluster randomized controlled trial. Trials 21:434

Renovanz M, Maurer D, Lahr H, Weimann E, Deininger M, Wirtz CR, Ringel F, Singer S, Coburger J (2018) Supportive Care Needs in Glioma Patients and Their Caregivers in Clinical Practice: Results of a Multicenter Cross-Sectional Study. Front Neurol 9:763

Renovanz M, Hechtner M, Kohlmann K, Janko M, Nadji-Ohl M, Singer S, Ringel F, Coburger J, Hickmann AK (2018) Compliance with patient-reported outcome assessment in glioma patients: predictors for drop out. Neurooncol Pract 5:129-38


DirectorDepartment of Neurology and Interdisciplinary Neuro-Oncology
Prof. Dr. Dr. Ghazaleh TabatabaiPhone 07071 29-85018ghazaleh.tabatabai@uni-tuebingen.deAddress

Center of Neurology
Hertie Institute for Clinical Brain Research
Department of Neurology & Interdisciplinary Neuro-Oncology

Otfried-Müller-Straße 27
72076 Tübingen

Phone: +49 (0)7071 29-85018
Fax: +49 (0)7071 29-5957


Susanne Luginsland
Phone: +49 (0)7071 29-83269
Fax: +49 (0)7071 29-5957

Karin Lohner
Phone: +49 (0)7071 29-85027
Fax: +49 (0)7071 29-5957